{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:47:51Z","timestamp":1788900471035,"version":"build-2803163510"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jns.2021.120015","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T04:45:34Z","timestamp":1633149934000},"page":"120015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Parkinsonism and dementia"],"prefix":"10.1016","volume":"433","author":[{"given":"Christos","family":"Koros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Stefanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Scarmeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":"Suppl. 2","key":"10.1016\/j.jns.2021.120015_bb0015","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/00019052-200312002-00004","article-title":"Dopamine and cognitive function","volume":"16","author":"Pillon","year":"2003","journal-title":"Curr. Opin. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0020","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/brain\/awaa411","article-title":"Cortical connectivity of the nucleus basalis of Meynert in Parkinson\u2019s disease and Lewy body dementias","volume":"144","author":"Oswal","year":"2021","journal-title":"Brain"},{"issue":"14","key":"10.1016\/j.jns.2021.120015_bb0025","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011699","article-title":"Cognitive profile and markers of Alzheimer disease-type pathology in patients With Lewy body dementias","volume":"96","author":"Howard","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.120015_bb0030","first-page":"2076942","article-title":"Cognition deficits in Parkinson\u2019s disease: mechanisms and treatment","volume":"2020","author":"Fang","year":"2020","journal-title":"Parkinsons Dis."},{"issue":"5","key":"10.1016\/j.jns.2021.120015_bb0035","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/gps.389","article-title":"A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia","volume":"16","author":"Aarsland","year":"2001","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.jns.2021.120015_bb0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2020.05.026","article-title":"Treatment of psychosis in Parkinson\u2019s disease and dementia with Lewy Bodies: a review","volume":"75","author":"Kyle","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.120015_bb0045","first-page":"2603641","article-title":"Pimavanserin treatment for Parkinson\u2019s disease psychosis in clinical practice","volume":"2021","author":"Dashtipour","year":"2021","journal-title":"Parkinsons Dis."},{"issue":"5","key":"10.1016\/j.jns.2021.120015_bb0050","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.25872","article-title":"Cognition in corticobasal syndrome and progressive supranuclear palsy: a review","volume":"29","author":"Burrell","year":"2014","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/mds.26874","article-title":"Profile of cognitive impairment and underlying pathology in multiple system atrophy","volume":"32","author":"Koga","year":"2017","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrneurol.2016.14","article-title":"Parkinsonism, movement disorders and genetics in frontotemporal dementia","volume":"12","author":"Baizabal-Carvallo","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2021.120015_bb0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.parkreldis.2020.06.005","article-title":"A novel mutation in PSEN1 (p.Arg41Ser) in an Argentinian woman with early onset Parkinsonism","volume":"77","author":"Gatto","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"issue":"5","key":"10.1016\/j.jns.2021.120015_bb0070","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/mds.25866","article-title":"The spectrum of cognitive impairment in Lewy body diseases","volume":"29","author":"Goldman","year":"2014","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.jns.2021.120015_bb0075","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1212\/01.WNL.0000036908.39696.FD","article-title":"Fluctuations in attention: PD dementia vs DLB with parkinsonism","volume":"59","author":"Ballard","year":"2002","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.jns.2021.120015_bb0080","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.jns.2021.120015_bb0085","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jnen\/nlw070","article-title":"Distribution and load of amyloid-beta pathology in Parkinson disease and dementia with Lewy bodies","volume":"75","author":"Hepp","year":"2016","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"20","key":"10.1016\/j.jns.2021.120015_bb0090","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009434","article-title":"Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies","volume":"94","author":"Smirnov","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jns.2021.120015_bb0095","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","article-title":"A systematic review of prevalence studies of dementia in Parkinson\u2019s disease","volume":"20","author":"Aarsland","year":"2005","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.jns.2021.120015_bb0100","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.62.8.1265","article-title":"Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study","volume":"62","author":"de Lau","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2021.120015_bb0105","article-title":"Meta-analysis of cognition in Parkinson\u2019s disease mild cognitive impairment and dementia progression","author":"Wallace","year":"2021","journal-title":"Neuropsychol. Rev."},{"issue":"8","key":"10.1016\/j.jns.2021.120015_bb0110","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1212\/WNL.54.8.1596","article-title":"A 10-year study of the incidence of and factors predicting dementia in Parkinson\u2019s disease","volume":"54","author":"Hughes","year":"2000","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jns.2021.120015_bb0115","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120015_bb0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jocn.2015.09.026","article-title":"The interlocking finger test in patients with Parkinson\u2019s disease and healthy subjects","volume":"29","author":"Souza","year":"2016","journal-title":"J. Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1474-4422(03)00351-X","article-title":"Dementia associated with Parkinson\u2019s disease","volume":"2","author":"Emre","year":"2003","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.jns.2021.120015_bb0130","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/jnnp.2010.234799","article-title":"Feeling of presence in Parkinson\u2019s disease","volume":"82","author":"Fenelon","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0135","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3233\/JPD-150604","article-title":"Neuropsychiatric symptoms in Parkinson\u2019s disease","volume":"5","author":"Aarsland","year":"2015","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.jns.2021.120015_bb0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2021.120015_bb0145","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1474-4422(21)00176-9","article-title":"Biomarkers of conversion to \u03b1-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder","volume":"20","author":"Miglis","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.120015_bb0150","doi-asserted-by":"crossref","DOI":"10.1007\/s11065-020-09473-1","article-title":"Sleep disorders and cognitive dysfunctions in Parkinson\u2019s disease: a meta-analytic study","author":"Maggi","year":"2021","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.jns.2021.120015_bb0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.parkreldis.2021.07.024","article-title":"Olfaction, cholinergic basal forebrain degeneration, and cognition in early Parkinson disease","volume":"90","author":"Barrett","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.27902","article-title":"Prevalence and clinical aspects of mild cognitive impairment in Parkinson\u2019s disease: a meta-analysis","volume":"35","author":"Baiano","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120015_bb0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnagi.2019.00021","article-title":"Incidence of mild cognitive impairment and dementia in Parkinson\u2019s disease: the Parkinson\u2019s disease cognitive impairment study","volume":"11","author":"Nicoletti","year":"2019","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0170","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mds.27617","article-title":"Risk of Parkinson\u2019s disease dementia related to level I MDS PD-MCI","volume":"34","author":"Hoogland","year":"2019","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.jns.2021.120015_bb0175","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/ane.13326","article-title":"Parkinson disease with mild cognitive impairment: Domain-specific cognitive complaints predict dementia","volume":"142","author":"Gasca-Salas","year":"2020","journal-title":"Acta Neurol. Scand."},{"issue":"19","key":"10.1016\/j.jns.2021.120015_bb0180","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007453","article-title":"Higher probability of prodromal Parkinson disease is related to lower cognitive performance","volume":"92","author":"Bougea","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.120015_bb0185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.parkreldis.2021.04.001","article-title":"Late life psychotic features in prodromal Parkinson\u2019s disease","volume":"86","author":"Pachi","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"issue":"10\u221211","key":"10.1016\/j.jns.2021.120015_bb0190","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00702-004-0168-1","article-title":"Cognitive dysfunction and dementia in Parkinson\u2019s disease","volume":"111","author":"Bosboom","year":"2004","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"12","key":"10.1016\/j.jns.2021.120015_bb0195","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","article-title":"Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study","volume":"60","author":"Bohnen","year":"2003","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2021.120015_bb0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0205","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archneur.59.1.102","article-title":"Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response","volume":"59","author":"Apaydin","year":"2002","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"Outeiro","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0215","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mds.10633","article-title":"Comparison of dementia with Lewy bodies to Alzheimer\u2019s disease and Parkinson\u2019s disease with dementia","volume":"19","author":"Noe","year":"2004","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.jns.2021.120015_bb0220","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/archneur.63.10.1450","article-title":"The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease","volume":"63","author":"Stavitsky","year":"2006","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0225","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-017-0242-1","article-title":"Cognitive profile in prodromal dementia with Lewy bodies","volume":"9","author":"Kemp","year":"2017","journal-title":"Alzheimers Res. Ther."},{"issue":"11","key":"10.1016\/j.jns.2021.120015_bb0230","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/jnnp-2014-309436","article-title":"Impaired imitation of gestures in mild dementia: comparison of dementia with Lewy bodies, Alzheimer\u2019s disease and vascular dementia","volume":"86","author":"Nagahama","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13195-021-00792-w","article-title":"Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results","volume":"13","author":"van de Beek","year":"2021","journal-title":"Alzheimers Res. Ther."},{"issue":"12","key":"10.1016\/j.jns.2021.120015_bb0240","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231720","article-title":"Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer\u2019s disease dementia","volume":"15","author":"Beach","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jns.2021.120015_bb0250","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1212\/01.wnl.0000242630.52203.8f","article-title":"Clinical phenotype of Parkinson disease dementia","volume":"67","author":"Galvin","year":"2006","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2021.120015_bb0255","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/mds.25048","article-title":"Brain amyloid and cognition in Lewy body diseases","volume":"27","author":"Gomperts","year":"2012","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.jns.2021.120015_bb0260","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/mds.26662","article-title":"Biomarkers for dementia and mild cognitive impairment in Parkinson\u2019s disease","volume":"31","author":"Delgado-Alvarado","year":"2016","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.jns.2021.120015_bb0265","article-title":"A\/T\/(N) profile in cerebrospinal fluid of Parkinson\u2019s disease with\/without cognitive impairment and dementia with Lewy bodies","volume":"10","author":"Bellomo","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"15","key":"10.1016\/j.jns.2021.120015_bb0270","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/mds.23287","article-title":"CSF Abeta(42) and tau in Parkinson\u2019s disease with cognitive impairment","volume":"25","author":"Montine","year":"2010","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0275","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","article-title":"Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study","volume":"16","author":"Schrag","year":"2017","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0280","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JAD-160322","article-title":"Cerebrospinal fluid Alzheimer\u2019s disease biomarkers across the spectrum of Lewy body diseases: results from a large multicenter cohort","volume":"54","author":"van Steenoven","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt255","article-title":"Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson\u2019s disease with dementia and dementia with Lewy bodies compared to Alzheimer\u2019s disease","volume":"6","author":"Hansson","year":"2014","journal-title":"Alzheimers Res. Ther."},{"issue":"7","key":"10.1016\/j.jns.2021.120015_bb0290","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010084","article-title":"NfL as a biomarker for neurodegeneration and survival in Parkinson disease","volume":"95","author":"Backstrom","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0295","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JAD-2011-110587","article-title":"Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-beta pathway","volume":"27","author":"Maetzler","year":"2011","journal-title":"J. Alzheimers Dis."},{"issue":"11","key":"10.1016\/j.jns.2021.120015_bb0300","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/mds.28206","article-title":"Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression","volume":"35","author":"Mollenhauer","year":"2020","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.jns.2021.120015_bb0305","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/bs11070094","article-title":"Lewy body dementias: a coin with two sides?","volume":"11","author":"Mil\u00e1n-Tom\u00e1s","year":"2021","journal-title":"Behav. Sci. (Basel)"},{"issue":"12","key":"10.1016\/j.jns.2021.120015_bb0310","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3174\/ajnr.A4055","article-title":"Subcortical atrophy is associated with cognitive impairment in mild Parkinson disease: a combined investigation of volumetric changes, cortical thickness, and vertex-based shape analysis","volume":"35","author":"Mak","year":"2014","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"2","key":"10.1016\/j.jns.2021.120015_bb0315","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3233\/JPD-202496","article-title":"The association of beta-amyloid with cognition and striatal dopamine in early, non-demented Parkinson\u2019s disease","volume":"11","author":"Oh","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0320","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1212\/WNL.0000000000008818","article-title":"beta-Amyloid PET and neuropathology in dementia with Lewy bodies","volume":"94","author":"Kantarci","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2021.120015_bb0325","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/WNL.56.5.643","article-title":"Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD","volume":"56","author":"Lobotesis","year":"2001","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jns.2021.120015_bb0330","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/acn3.50877","article-title":"(11) C-PK11195 PET imaging and white matter changes in Parkinson\u2019s disease dementia","volume":"6","author":"Nicastro","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2021.120015_bb0335","doi-asserted-by":"crossref","first-page":"102200","DOI":"10.1016\/j.nicl.2020.102200","article-title":"Correlation of microglial activation with white matter changes in dementia with Lewy bodies","volume":"25","author":"Nicastro","year":"2020","journal-title":"Neuroimage Clin."},{"issue":"9","key":"10.1016\/j.jns.2021.120015_bb0340","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/diagnostics10090616","article-title":"The role of EEG in the diagnosis, prognosis and clinical correlations of dementia with Lewy bodies-a systematic review","volume":"10","author":"Law","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.jns.2021.120015_bb0345","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa207","article-title":"Cognitive decline in Parkinson\u2019s disease is associated with reduced complexity of EEG at baseline","volume":"2","author":"Keller","year":"2020","journal-title":"Brain Commun."},{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0350","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/mds.28424","article-title":"Soluble CD163 changes indicate monocyte association with cognitive deficits in Parkinson\u2019s disease","volume":"36","author":"Nissen","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120015_bb0355","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.parkreldis.2020.11.025","article-title":"Correlations between retinal nerve fiber layer thickness and cognitive progression in Parkinson\u2019s disease: a longitudinal study","volume":"82","author":"Zhang","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0360","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ana.25944","article-title":"Retinal thickness predicts the risk of cognitive decline in Parkinson disease","volume":"89","author":"Murueta-Goyena","year":"2021","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2021.120015_bb0365","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archneur.64.9.1242","article-title":"The relationship of Parkinson disease with aging","volume":"64","author":"Levy","year":"2007","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2021.120015_bb0370","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/jnnp.2005.081711","article-title":"Motor subtype and cognitive decline in Parkinson\u2019s disease, Parkinson\u2019s disease with dementia, and dementia with Lewy bodies","volume":"77","author":"Burn","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2021.120015_bb0375","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00415-020-10367-8","article-title":"Differential effects of sex on longitudinal patterns of cognitive decline in Parkinson\u2019s disease","volume":"268","author":"Bakeberg","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2021.120015_bb0380","doi-asserted-by":"crossref","first-page":"631145","DOI":"10.3389\/fneur.2021.631145","article-title":"APOE and MAPT are associated with dementia in neuropathologically confirmed Parkinson\u2019s disease","volume":"12","author":"Tunold","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2021.120015_bb0385","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.parkreldis.2021.01.004","article-title":"Impact of the apolipoprotein E epsilon4 allele on early Parkinson\u2019s disease progression","volume":"83","author":"Kim","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.120015_bb0390","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.sleep.2021.01.042","article-title":"Objective sleep data as predictors of cognitive decline in dementia with Lewy Bodies and Parkinson\u2019s disease","volume":"80","author":"Bugalho","year":"2021","journal-title":"Sleep Med."},{"issue":"2","key":"10.1016\/j.jns.2021.120015_bb0395","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.10086","article-title":"Do risk factors for Alzheimer\u2019s disease predict dementia in Parkinson\u2019s disease? An exploratory study","volume":"17","author":"Levy","year":"2002","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.jns.2021.120015_bb0400","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/mds.26698","article-title":"Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson\u2019s disease","volume":"31","author":"Malek","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120015_bb0405","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/bs.irn.2017.01.009","article-title":"Genetics of Parkinson\u2019s disease: genotype-phenotype correlations","volume":"132","author":"Koros","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"issue":"8","key":"10.1016\/j.jns.2021.120015_bb0410","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/mds.26615","article-title":"Motor and nonmotor features of carriers of the p.A53T alpha-synuclein mutation: a longitudinal study","volume":"31","author":"Papadimitriou","year":"2016","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.jns.2021.120015_bb0415","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005063","article-title":"Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD","volume":"90","author":"Koros","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2021.120015_bb0420","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jocn.2005.11.040","article-title":"Dementia with Lewy bodies in an elderly Greek male due to alpha-synuclein gene mutation","volume":"13","author":"Morfis","year":"2006","journal-title":"J. Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.jns.2021.120015_bb0425","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.parkreldis.2009.06.007","article-title":"A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction","volume":"15","author":"Puschmann","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.120015_bb0430","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.parkreldis.2016.12.002","article-title":"Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene","volume":"35","author":"Bougea","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.jns.2021.120015_bb0435","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2011.07.047","article-title":"Initial neuropsychological impairments in patients with the E46K mutation of the alpha-synuclein gene (PARK 1)","volume":"310","author":"Somme","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.jns.2021.120015_bb0440","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1212\/WNL.56.10.1355","article-title":"Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers","volume":"56","author":"Kruger","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2021.120015_bb0445","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/mds.25421","article-title":"Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson\u2019s disease","volume":"28","author":"Appel-Cresswell","year":"2013","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.jns.2021.120015_bb0450","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/mds.28534","article-title":"A novel SNCA A30G mutation causes familial Parkinson\u2019s disease","volume":"36","author":"Liu","year":"2021","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.jns.2021.120015_bb0455","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.parkreldis.2015.06.005","article-title":"Early-onset parkinsonism caused by alpha-synuclein gene triplication: clinical and genetic findings in a novel family","volume":"21","author":"Olgiati","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"issue":"6","key":"10.1016\/j.jns.2021.120015_bb0460","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.21380","article-title":"Genomic investigation of alpha-synuclein multiplication and parkinsonism","volume":"63","author":"Ross","year":"2008","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2021.120015_bb0465","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.parkreldis.2014.02.021","article-title":"Does alpha-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson\u2019s disease?","volume":"20","author":"Markopoulou","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"7","key":"10.1016\/j.jns.2021.120015_bb0470","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2021.120015_bb0475","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.parkreldis.2014.09.033","article-title":"Neuropsychological performance in LRRK2 G2019S carriers with Parkinson\u2019s disease","volume":"21","author":"Alcalay","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0480","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"GBA-associated Parkinson\u2019s disease: reduced survival and more rapid progression in a prospective longitudinal study","volume":"30","author":"Brockmann","year":"2015","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0485","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JPD-171221","article-title":"Phenotypic characteristics in GBA-associated Parkinson\u2019s disease: a study in a Greek population","volume":"8","author":"Simitsi","year":"2018","journal-title":"J. Parkinsons Dis."},{"issue":"Pt 8","key":"10.1016\/j.jns.2021.120015_bb0490","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/brain\/awu143","article-title":"Visual short-term memory deficits associated with GBA mutation and Parkinson\u2019s disease","volume":"137","author":"Zokaei","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.jns.2021.120015_bb0495","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.nbd.2016.06.004","article-title":"Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies","volume":"94","author":"Geiger","year":"2016","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0500","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jamaneurol.2013.4498","article-title":"Cognitive and motor function in long-duration PARKIN-associated Parkinson disease","volume":"71","author":"Alcalay","year":"2014","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0505","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/humu.20719","article-title":"PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum","volume":"29","author":"Marongiu","year":"2008","journal-title":"Hum. Mutat."},{"issue":"Pt 6","key":"10.1016\/j.jns.2021.120015_bb0510","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/brain\/aww080","article-title":"DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology","volume":"139","author":"Taipa","year":"2016","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.jns.2021.120015_bb0515","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease","volume":"21","author":"Burn","year":"2006","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0520","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/01.wnf.0000172498.24770.54","article-title":"Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study","volume":"28","author":"Linazasoro","year":"2005","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0525","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/jnnp.2008.144048","article-title":"A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease","volume":"80","author":"Grace","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2021.120015_bb0530","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2013-306439","article-title":"Rivastigmine in apathetic but dementia and depression-free patients with Parkinson\u2019s disease: a double-blind, placebo-controlled, randomised clinical trial","volume":"85","author":"Devos","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2021.120015_bb0535","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14802\/jmd.15041","article-title":"Effect of rivastigmine on behavioral and psychiatric symptoms of Parkinson\u2019s disease dementia","volume":"8","author":"Oh","year":"2015","journal-title":"J. Mov. Disord."},{"issue":"12","key":"10.1016\/j.jns.2021.120015_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243437","article-title":"The side effect profile of Clozapine in real world data of three large mental health hospitals","volume":"15","author":"Iqbal","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jns.2021.120015_bb0545","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40266-019-00655-y","article-title":"Pimavanserin for psychosis in Parkinson\u2019s disease-related disorders: a retrospective chart review","volume":"36","author":"Sellers","year":"2019","journal-title":"Drugs Aging"},{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0550","article-title":"Treatment of Parkinson\u2019s disease with cognitive impairment: current approaches and future directions","volume":"11","author":"Sun","year":"2021","journal-title":"Behav. Sci. (Basel)"},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0555","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s10020-021-00279-2","article-title":"Novel targeted therapies for Parkinson\u2019s disease","volume":"27","author":"Ntetsika","year":"2021","journal-title":"Mol. Med."},{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0560","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-015-7657-z","article-title":"Cognitive-behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia","volume":"262","author":"Kobylecki","year":"2015","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2021.120015_bb0565","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00702-019-02065-1","article-title":"Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson\u2019s disease","volume":"126","author":"Fiorenzato","year":"2019","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"5","key":"10.1016\/j.jns.2021.120015_bb0570","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp-2012-303618","article-title":"The Addenbrooke\u2019s cognitive examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders","volume":"84","author":"Rittman","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0575","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jnnp.60.4.403","article-title":"Progressive supranuclear palsy presenting with dynamic aphasia","volume":"60","author":"Esmonde","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2021.120015_bb0580","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mds.22902","article-title":"Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy","volume":"25","author":"O\u2019Sullivan","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120015_bb0585","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jns.2017.07.033","article-title":"Executive dysfunction, behavioral changes and quality of life in Chinese patients with progressive supranuclear palsy","volume":"380","author":"Ou","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.jns.2021.120015_bb0590","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.10583","article-title":"Health-related quality of life in patients with progressive supranuclear palsy","volume":"18","author":"Schrag","year":"2003","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0595","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s00415-011-6205-8","article-title":"The relationship between clinical and pathological variables in Richardson\u2019s syndrome","volume":"259","author":"Schofield","year":"2012","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2021.120015_bb0600","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1212\/WNL.58.7.1013","article-title":"Cholinergic vesicular transporters in progressive supranuclear palsy","volume":"58","author":"Suzuki","year":"2002","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2021.120015_bb0605","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archneurol.2011.107","article-title":"Clinical correlates of white matter tract degeneration in progressive supranuclear palsy","volume":"68","author":"Whitwell","year":"2011","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2021.120015_bb0610","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0615","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1212\/WNL.54.4.990","article-title":"Language disturbances in corticobasal degeneration","volume":"54","author":"Frattali","year":"2000","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2021.120015_bb0620","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1212\/WNL.55.9.1368","article-title":"The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia","volume":"55","author":"Kertesz","year":"2000","journal-title":"Neurology"},{"issue":"Pt 5","key":"10.1016\/j.jns.2021.120015_bb0625","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/brain\/117.5.1183","article-title":"Corticobasal degeneration. A clinical study of 36 cases","volume":"117","author":"Rinne","year":"1994","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jns.2021.120015_bb0630","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/1460-6984.12559","article-title":"Progressive aphasia, apraxia of speech and agraphia in corticobasal degeneration: a 12-case series clinical and neuropsychological descriptive study","volume":"55","author":"Ruggeri","year":"2020","journal-title":"Int. J. Lang. Commun. Disord."},{"key":"10.1016\/j.jns.2021.120015_bb0635","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.parkreldis.2018.12.006","article-title":"Quantifying apraxia and ophthalmokinetic abnormalities in patients with atypical Parkinsonism: a new way to differential diagnosis?","volume":"61","author":"Constantinides","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"issue":"8","key":"10.1016\/j.jns.2021.120015_bb0640","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.WNL.0000086814.35352.B3","article-title":"Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction","volume":"61","author":"Tang-Wai","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0645","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.2003.029595","article-title":"Cognitive bedside assessment in atypical parkinsonian syndromes","volume":"76","author":"Bak","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0650","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/13554790701448192","article-title":"Dysfunctional facial emotional expression and comprehension in a patient with corticobasal degeneration","volume":"13","author":"Kluger","year":"2007","journal-title":"Neurocase"},{"key":"10.1016\/j.jns.2021.120015_bb0655","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2019.01.046","article-title":"Clinical, neuropsychological and imaging characteristics of Alzheimer\u2019s disease patients presenting as corticobasal syndrome","volume":"398","author":"Constantinides","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.jns.2021.120015_bb0660","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/mds.28624","article-title":"Cortical [(18) F]PI-2620 binding differentiates corticobasal syndrome subtypes","volume":"36","author":"Palleis","year":"2021","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0665","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/archneur.63.1.81","article-title":"Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy","volume":"63","author":"Boxer","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2021.120015_bb0670","doi-asserted-by":"crossref","first-page":"537360","DOI":"10.3389\/fneur.2020.537360","article-title":"Cognitive profile and its evolution in a cohort of multiple system atrophy patients","volume":"11","author":"Sambati","year":"2020","journal-title":"Front. Neurol."},{"issue":"Pt 8","key":"10.1016\/j.jns.2021.120015_bb0675","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awq158","article-title":"Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy","volume":"133","author":"Brown","year":"2010","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jns.2021.120015_bb0680","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00702-020-02169-z","article-title":"Effects of gender on cognitive and behavioral manifestations in multiple system atrophy","volume":"127","author":"Cuoco","year":"2020","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"10","key":"10.1016\/j.jns.2021.120015_bb0685","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1468-1331.2009.02661.x","article-title":"Cognitive deficits in multiple system atrophy correlate with frontal atrophy and disease duration","volume":"16","author":"Chang","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2021.120015_bb0690","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0278-2626(02)00503-1","article-title":"Patterns of neuropsychological performance in multiple system atrophy compared to sporadic and hereditary olivopontocerebellar atrophy","volume":"50","author":"Berent","year":"2002","journal-title":"Brain Cogn."},{"issue":"16 Pt 2","key":"10.1016\/j.jns.2021.120015_bb0695","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000310413.04462.6a","article-title":"Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P","volume":"70","author":"Kawai","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0700","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/archneur.55.3.372","article-title":"Cognitive dysfunction and impaired organization of complex motility in degenerative parkinsonian syndromes","volume":"55","author":"Monza","year":"1998","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2021.120015_bb0705","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.parkreldis.2019.12.010","article-title":"Evolution of neuropsychological profile in motor subtypes of multiple system atrophy","volume":"70","author":"Santangelo","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0710","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1440-1789.2007.00759.x","article-title":"A quantitative study of the pathological changes in white matter in multiple system atrophy","volume":"27","author":"Armstrong","year":"2007","journal-title":"Neuropathology"},{"issue":"18","key":"10.1016\/j.jns.2021.120015_bb0715","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.0b013e3181dc1a55","article-title":"Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes","volume":"74","author":"Gilman","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2021.120015_bb0720","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cns.13068","article-title":"Available and future treatments for atypical parkinsonism. A systematic review","volume":"25","author":"Moretti","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jns.2021.120015_bb0725","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/bs.irn.2019.10.012","article-title":"Parkinsonism in frontotemporal dementias","volume":"149","author":"Rowe","year":"2019","journal-title":"Int. Rev. Neurobiol."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0730","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mdc3.13100","article-title":"Japanese familial cases of frontotemporal dementia and Parkinsonism with N279K Tau gene mutation","volume":"8","author":"Oka","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"2","key":"10.1016\/j.jns.2021.120015_bb0735","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000575","article-title":"Expanding the spectrum of movement disorders associated with C9orf72 hexanucleotide expansions","volume":"7","author":"Estevez-Fraga","year":"2021","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.jns.2021.120015_bb0740","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.parkreldis.2020.09.019","article-title":"Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations","volume":"80","author":"Carneiro","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0745","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3233\/JAD-190469","article-title":"Dopa responsive Parkinsonism in an early onset Alzheimer\u2019s disease patient with a Presenilin 1 mutation (A434T)","volume":"71","author":"Jo","year":"2019","journal-title":"J. Alzheimers Dis."},{"issue":"10","key":"10.1016\/j.jns.2021.120015_bb0750","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1212\/01.WNL.0000162054.15428.E9","article-title":"Motor signs predict poor outcomes in Alzheimer disease","volume":"64","author":"Scarmeas","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0755","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/S1980-57642012DN06030005","article-title":"Vascular Parkinsonism and cognitive impairment: literature review, Brazilian studies and case vignettes","volume":"6","author":"Vale","year":"2012","journal-title":"Dement Neuropsychol."},{"key":"10.1016\/j.jns.2021.120015_bb0760","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.parkreldis.2019.06.025","article-title":"Juvenile parkinsonism: differential diagnosis, genetics, and treatment","volume":"67","author":"Niemann","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/j.jns.2021.120015_bb0765","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/cld.1041","article-title":"The present and future challenges of Wilson\u2019s disease diagnosis and treatment","volume":"17","author":"Leung","year":"2021","journal-title":"Clin. Liver Dis."},{"issue":"1","key":"10.1016\/j.jns.2021.120015_bb0770","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mds.10650","article-title":"Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration","volume":"19","author":"Thomas","year":"2004","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.jns.2021.120015_bb0775","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/mds.22953","article-title":"Cognitive and functional decline in Huntington\u2019s disease: dementia criteria revisited","volume":"25","author":"Peavy","year":"2010","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jns.2021.120015_bb0780","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ana.10676","article-title":"Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17)","volume":"54","author":"Rolfs","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2021.120015_bb0785","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5334\/tohm.439","article-title":"Dentatorubral-pallidoluysian atrophy: an update","volume":"8","author":"Carroll","year":"2018","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"6","key":"10.1016\/j.jns.2021.120015_bb0790","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.neuropsychologia.2004.10.001","article-title":"Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson\u2019s disease","volume":"43","author":"Lewis","year":"2005","journal-title":"Neuropsychologia"},{"issue":"11","key":"10.1016\/j.jns.2021.120015_bb0795","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","article-title":"A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes","volume":"86","author":"Magdalinou","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.120015_bb0800","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jns.2017.09.039","article-title":"CSF biomarkers \u03b2-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes","volume":"382","author":"Constantinides","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2021.120015_bb0805","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.parkreldis.2020.11.016","article-title":"Cerebrospinal fluid biomarker profiling in corticobasal degeneration: application of the AT (N) and other classification systems","volume":"82","author":"Constantinides","year":"2020","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:59:54Z","timestamp":1758383994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21027118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":161,"alternative-id":["S0022510X21027118"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.120015","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parkinsonism and dementia","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.120015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120015"}}